These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
303 related articles for article (PubMed ID: 28570161)
1. A Phase II Clinical Trial of an Aromatase Inhibitor for Postmenopausal Women with Lymphangioleiomyomatosis. Lu C; Lee HS; Pappas GP; Dilling DF; Burger CD; Shifren A; Veeraraghavan S; Chapman JT; Parambil J; Ruoss SJ; Young LR; Hammes SR; Kopras EJ; Roads T; Krischer JP; McCormack FX; Ann Am Thorac Soc; 2017 Jun; 14(6):919-928. PubMed ID: 28570161 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. McCormack FX; Inoue Y; Moss J; Singer LG; Strange C; Nakata K; Barker AF; Chapman JT; Brantly ML; Stocks JM; Brown KK; Lynch JP; Goldberg HJ; Young LR; Kinder BW; Downey GP; Sullivan EJ; Colby TV; McKay RT; Cohen MM; Korbee L; Taveira-DaSilva AM; Lee HS; Krischer JP; Trapnell BC; ; N Engl J Med; 2011 Apr; 364(17):1595-606. PubMed ID: 21410393 [TBL] [Abstract][Full Text] [Related]
3. Sirolimus and Autophagy Inhibition in Lymphangioleiomyomatosis: Results of a Phase I Clinical Trial. El-Chemaly S; Taveira-Dasilva A; Goldberg HJ; Peters E; Haughey M; Bienfang D; Jones AM; Julien-Williams P; Cui Y; Villalba JA; Bagwe S; Maurer R; Rosas IO; Moss J; Henske EP Chest; 2017 Jun; 151(6):1302-1310. PubMed ID: 28192114 [TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and safety of sirolimus therapy in patients with lymphangioleiomyomatosis. Hu S; Wu X; Xu W; Tian X; Yang Y; Wang ST; Liu S; Xu X; Xu KF Orphanet J Rare Dis; 2019 Aug; 14(1):206. PubMed ID: 31429781 [TBL] [Abstract][Full Text] [Related]
5. Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. Young L; Lee HS; Inoue Y; Moss J; Singer LG; Strange C; Nakata K; Barker AF; Chapman JT; Brantly ML; Stocks JM; Brown KK; Lynch JP; Goldberg HJ; Downey GP; Swigris JJ; Taveira-DaSilva AM; Krischer JP; Trapnell BC; McCormack FX; Lancet Respir Med; 2013 Aug; 1(6):445-52. PubMed ID: 24159565 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Long-Term Sirolimus Therapy for Asian Patients with Lymphangioleiomyomatosis. Takada T; Mikami A; Kitamura N; Seyama K; Inoue Y; Nagai K; Suzuki M; Moriyama H; Akasaka K; Tazawa R; Hirai T; Mishima M; Hayashida M; Hirose M; Sugimoto C; Arai T; Hattori N; Watanabe K; Tamada T; Yoshizawa H; Akazawa K; Tanaka T; Yagi K; Young LR; McCormack FX; Nakata K Ann Am Thorac Soc; 2016 Nov; 13(11):1912-1922. PubMed ID: 27513278 [TBL] [Abstract][Full Text] [Related]
7. Long-Term Effect of Sirolimus on Serum Vascular Endothelial Growth Factor D Levels in Patients With Lymphangioleiomyomatosis. Taveira-DaSilva AM; Jones AM; Julien-Williams P; Stylianou M; Moss J Chest; 2018 Jan; 153(1):124-132. PubMed ID: 28533049 [TBL] [Abstract][Full Text] [Related]
8. Serum vascular endothelial growth factor-D as a diagnostic and therapeutic biomarker for lymphangioleiomyomatosis. Hirose M; Matsumuro A; Arai T; Sugimoto C; Akira M; Kitaichi M; Young LR; McCormack FX; Inoue Y PLoS One; 2019; 14(2):e0212776. PubMed ID: 30818375 [TBL] [Abstract][Full Text] [Related]
10. Diagnostic and Treatment Monitoring Potential of Serum Vascular Endothelial Growth Factor-D in Lymphangioleiomyomatosis. Mou Y; Ye L; Wang J; Yee MS; Song YL; Zhu L; Jin ML Lymphology; 2016 Sep; 49(3):140-9. PubMed ID: 29906075 [TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. Seyama K; Kumasaka T; Souma S; Sato T; Kurihara M; Mitani K; Tominaga S; Fukuchi Y Lymphat Res Biol; 2006; 4(3):143-52. PubMed ID: 17034294 [TBL] [Abstract][Full Text] [Related]
12. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449 [TBL] [Abstract][Full Text] [Related]
14. Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis. Gupta N; Lee HS; Young LR; Strange C; Moss J; Singer LG; Nakata K; Barker AF; Chapman JT; Brantly ML; Stocks JM; Brown KK; Lynch JP; Goldberg HJ; Downey GP; Taveira-DaSilva AM; Krischer JP; Setchell K; Trapnell BC; Inoue Y; McCormack FX; Eur Respir J; 2019 Apr; 53(4):. PubMed ID: 30846465 [TBL] [Abstract][Full Text] [Related]
15. A Novel Quantitative Computed Tomographic Analysis Suggests How Sirolimus Stabilizes Progressive Air Trapping in Lymphangioleiomyomatosis. Argula RG; Kokosi M; Lo P; Kim HJ; Ravenel JG; Meyer C; Goldin J; Lee HS; Strange C; McCormack FX; Ann Am Thorac Soc; 2016 Mar; 13(3):342-9. PubMed ID: 26799509 [TBL] [Abstract][Full Text] [Related]
16. Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial. Azria D; Belkacemi Y; Romieu G; Gourgou S; Gutowski M; Zaman K; Moscardo CL; Lemanski C; Coelho M; Rosenstein B; Fenoglietto P; Crompton NE; Ozsahin M Lancet Oncol; 2010 Mar; 11(3):258-65. PubMed ID: 20138810 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer. Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524 [TBL] [Abstract][Full Text] [Related]
18. Functional improvements in patients with lymphangioleiomyomatosis after sirolimus: an observational study. Zhan Y; Shen L; Xu W; Wu X; Zhang W; Wang J; Li X; Yang Y; Tian X; Xu KF Orphanet J Rare Dis; 2018 Feb; 13(1):34. PubMed ID: 29458386 [TBL] [Abstract][Full Text] [Related]
19. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G; Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065 [TBL] [Abstract][Full Text] [Related]
20. Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis. Lamattina AM; Taveira-Dasilva A; Goldberg HJ; Bagwe S; Cui Y; Rosas IO; Moss J; Henske EP; El-Chemaly S Chest; 2018 Nov; 154(5):1070-1082. PubMed ID: 30144422 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]